Efficacy and safety of immune checkpoint inhibitors in colorectal cancer: a systematic review and meta-analysis.

医学 荟萃分析 内科学 结直肠癌 肿瘤科 无容量 癌症 科克伦图书馆 肝病学 彭布罗利珠单抗 不利影响 梅德林 随机对照试验 易普利姆玛 临床试验
作者
Tianni Zeng,Xiaojie Fang,Jinhua Lu,Yazhen Zhong,Xianlei Lin,Zechen Lin,Nan Wang,Jing Jiang,Shengyou Lin
出处
期刊:International Journal of Colorectal Disease [Springer Nature]
卷期号:: 1-8
标识
DOI:10.1007/s00384-021-04028-z
摘要

Background and objective Immune checkpoint inhibitor (ICI) therapies have shown promising prospects in colorectal cancer (CRC) immunotherapy; many clinical trials have been carried out. In this study, we sought to evaluate the efficacy and safety of ICI therapies in CRC by presenting a meta-analysis of relevant studies. Methods Databases including PubMed, Embase, Cochrane Library, and Web of Science were systematically searched for studies concerning the efficacy and safety of ICI in colorectal cancer. The reported odds ratio (OR) or weighted mean difference (WMD) with 95% confidence intervals (CIs) of overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), treatment-related adverse events (TRAEs), and TRAEs ≥ 3 in the included studies were analyzed by fixed effects/random effects models. Results Three studies involving 667 patients with colorectal cancer were included in our meta-analysis. No significant difference between the immune checkpoint inhibitor therapies and conventional therapies in OS (WMD = 0.73, 95% CI - 3.09, 4.54; p = 0.71), in ORR (OR = 1.54, 95% CI 0.98, 2.40; p = 0.06), and in DCR (OR = 0.97, 95% CI 0.36, 2.61; p = 0.95). The median PFS of the ICI therapy group was shorter than that of the conventional therapy group (WMD = - 0.10, 95% CI - 0.18, - 0.02; p = 0.02). At the same time, we also could not find a significant difference between the immune checkpoint inhibitor therapies and conventional therapies in TRAEs (OR = 1.56, 95% CI 0.11, 22.09; p = 0.74) and in TRAEs ≥ 3 (OR = 0.94, 95% CI 0.16, 5.65; p = 0.95). Conclusion Immune checkpoint inhibitor therapies could not improve all survival endpoints to advanced or metastatic colorectal cancer patients. Whether immune checkpoint inhibitors should be the first choice of therapies for colorectal cancer patients with undetermined microsatellite status or not able to determine microsatellite status needs more related studies to prove.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
make217完成签到 ,获得积分10
1秒前
lod完成签到,获得积分10
2秒前
科研通AI2S应助stargazor采纳,获得10
4秒前
言文言完成签到,获得积分10
5秒前
daixan89完成签到,获得积分10
5秒前
千桑客完成签到,获得积分10
8秒前
路路完成签到 ,获得积分10
10秒前
伍子丐的猫完成签到,获得积分10
13秒前
共渡完成签到,获得积分10
14秒前
陈荣完成签到 ,获得积分10
16秒前
一只蓉馍馍完成签到,获得积分10
17秒前
Akim应助Raymond采纳,获得10
17秒前
缓慢雅青完成签到 ,获得积分10
19秒前
赘婿应助Longy采纳,获得10
20秒前
小紫完成签到 ,获得积分10
20秒前
加油完成签到,获得积分10
21秒前
小新完成签到 ,获得积分10
23秒前
超帅连虎完成签到,获得积分10
25秒前
nav完成签到 ,获得积分10
25秒前
袁翰将军完成签到 ,获得积分10
27秒前
Cynthia完成签到 ,获得积分10
31秒前
skycool完成签到,获得积分10
33秒前
凯撒的归凯撒完成签到 ,获得积分10
34秒前
iehaoang完成签到 ,获得积分10
35秒前
皮皮虾完成签到,获得积分10
37秒前
淞33完成签到 ,获得积分10
37秒前
木棉完成签到,获得积分10
39秒前
ty完成签到,获得积分10
44秒前
李友健完成签到 ,获得积分10
45秒前
48秒前
月光完成签到,获得积分10
49秒前
Lucas应助zhangzhisenn采纳,获得30
49秒前
阿湫完成签到,获得积分10
49秒前
51秒前
CO2完成签到,获得积分10
51秒前
53秒前
明月清风完成签到,获得积分10
53秒前
CodeCraft应助Li采纳,获得10
54秒前
keroro完成签到,获得积分10
55秒前
daishuheng完成签到 ,获得积分10
56秒前
高分求助中
Solution Manual for Strategic Compensation A Human Resource Management Approach 1200
Natural History of Mantodea 螳螂的自然史 1000
Glucuronolactone Market Outlook Report: Industry Size, Competition, Trends and Growth Opportunities by Region, YoY Forecasts from 2024 to 2031 800
A Photographic Guide to Mantis of China 常见螳螂野外识别手册 800
Autoregulatory progressive resistance exercise: linear versus a velocity-based flexible model 500
The analysis and solution of partial differential equations 400
Sociocultural theory and the teaching of second languages 300
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 细胞生物学 免疫学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3339197
求助须知:如何正确求助?哪些是违规求助? 2967064
关于积分的说明 8628229
捐赠科研通 2646594
什么是DOI,文献DOI怎么找? 1449297
科研通“疑难数据库(出版商)”最低求助积分说明 671343
邀请新用户注册赠送积分活动 660180